https://www.bioworld.com/rss en-us A single-cell transcriptomics study of the fetal-maternal tissue interface in preeclampsia at different stages of gestation provides new information about the distinct maternal and fetal cell processes contributing to the serious pregnancy complication and points in the direction of potential therapeutic targets. http://www.bioworld.com/articles/732993 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732993-single-cell-transcriptome-study-points-to-new-drug-targets-for-preeclampsia Pregnant woman having blood pressure tested Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s architecture is shaped through the organization of tissues, the establishment of molecular pathways, and the coordination of signals that will later sustain the body as an integrated system. It is likely the most delicate stage of life, where any disturbance in that foundational process can have lasting consequences on health. http://www.bioworld.com/articles/732374 Fri, 03 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732374-cinp-2026-prenatal-and-adolescent-stress-shape-brain-vulnerability At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and Psychiatry (NCNP) showcased how human organoid technologies are reshaping the study of neurodevelopmental vulnerability, addiction and psychiatric disorders. http://www.bioworld.com/articles/732329 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732329-cinp-2026-organoids-reveal-autism-and-addiction-mechanisms AI-generated image for brain organoid neural research Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have described tachykinin NK3 receptor antagonists that are potentially useful for the treatment of menopausal symptoms, polycystic ovarian syndrome, uterine fibroids (myoma), schizophrenia, irritable bowel syndrome and breast cancer. http://www.bioworld.com/articles/732121 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732121-hansoh-identifies-new-nk3-receptor-antagonists WAVES, an algorithm designed to extract menstrual-cycle metrics from physiological signals such as basal body temperature, which oscillates with sex hormones, shows how different parameters change with age and helps determine whether each person maintains a stable individual pattern or personal footprint. A study based on data from 5,674 cycles from 753 women demonstrates through this tool that age is associated with higher temperatures, shorter cycles, and greater irregularity. In addition, several metrics show within-person stability, suggesting they could serve as personalized health markers. http://www.bioworld.com/articles/731248 Fri, 22 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731248-menstrual-footprints-may-act-as-broad-personal-health-markers Female uterus and ovaries on abstract scientific background Maipl Therapeutics Inc. has outlined preclinical progress with MA-4604, its lead investigational therapy for endometriosis. http://www.bioworld.com/articles/731123 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731123-maipl-therapeutics-advances-ma-4604-for-endometriosis Seven years, almost to the day, after releasing a draft guidance on post-approval pregnancy safety studies, the U.S. FDA is now finalizing it – albeit with a few changes. http://www.bioworld.com/articles/731033 Mon, 11 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731033-fda-pregnancy-safety-guidance-evolves-with-the-science Pregnancy Changchun Genescience Pharmaceuticals Co. Ltd. has prepared and tested new steroid compounds acting as estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) inhibitors that are potentially useful for the treatment of endometriosis. http://www.bioworld.com/articles/730068 Wed, 01 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730068-changchun-genescience-pharmaceuticals-discloses-new-17-hsd1-inhibitors Insilico Medicine Cayman Topco has established a strategic research collaboration with Aska Pharmaceutical Co. Ltd. to identify novel therapeutic targets for challenging gynecological conditions, including endometriosis, uterine fibroids and adenomyosis. http://www.bioworld.com/articles/729879 Wed, 25 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729879-insilico-medicine-and-aska-enter-gynecological-collaboration Futuristic medical hologram illustration featuring the female reproductive system Endomet Biosciences Inc. (dba Endocyclic Therapeutics) has obtained IND clearance from the FDA for its lead program, ENDO-205, a first-in-class, nonhormonal targeted peptide therapeutic for endometriosis. http://www.bioworld.com/articles/729860 Tue, 24 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729860-endocyclics-endo-205-gains-ind-clearance-for-endometriosis Teijin Pharma Ltd. has entered into a joint research agreement with Aska Pharmaceutical Co. Ltd. to jointly develop novel small-molecule drug candidates for gynecological diseases. http://www.bioworld.com/articles/728899 Tue, 17 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728899-teijin-pharma-and-aska-partner-in-gynecological-diseases Illustration of women's reproductive organs Laborie Medical Technologies Corp. secured a new gem for its maternal health with the acquisition of the Jada system from Organon & Co. The terms of the deal, first announced in November, included payment of $440 million at closing, with an additional $25 million tied to 2026 revenue targets. http://www.bioworld.com/articles/728284 Fri, 30 Jan 2026 11:00:00 -0500 https://www.bioworld.com/articles/728284-laborie-acquires-jada-from-organon-in-465m-deal Jada device image Jada system for treatment of postpartum hemorrhage. Credit: Alydia Health greg.kaplan@clarivate.com Prenaital ApS has filed a patent for technology that may identify risks of spontaneous pre-term birth. Spontaneous preterm birth (sPTB) is usually defined as birth occurring before 37 weeks of gestation. The invention relates to a method for predicting potential preterm birth from medical scan data, which may be used in practice by medical professionals for risk analysis and prognosis of potential pathologies. The invention relates to a method for predicting potential preterm birth from medical scan data, which may be used in practice by medical professionals for risk analysis and prognosis of potential pathologies. ]]> http://www.bioworld.com/articles/728085 Fri, 23 Jan 2026 11:00:00 -0500 https://www.bioworld.com/articles/728085-ai-identifies-pregnancies-at-risk-of-spontaneous-pre-term-birth Prenaital CEO and co-founders From left: Prenaital CEO and co-founder Tanja Danner, DTU professor and co-founder Aasa Feragen and Martin G. Tolsgaard, co-founder and senior physician at Rigshospitalet. Credit: Courtesy DTU. Genedx Holding Corp. launched Genomedx Prenatal, its whole genome sequencing test, to provide more definitive diagnoses of the causes of fetal abnormalities identified by ultrasound. By combining the company’s decade of experience in prenatal exome testing and its massive Genedx Infinity rare disease dataset, the test can determine not just whether a pregnancy has a risk of a genetic disorder but whether the fetus actually has a genetic disorder. http://www.bioworld.com/articles/727585 Wed, 07 Jan 2026 11:00:00 -0500 https://www.bioworld.com/articles/727585-genedx-delivers-wgs-prenatal-testing Genedx’s Director of Laboratory Innovation Joe Devaney Genedx’s director of laboratory innovation Joe Devaney. Credit: Genedx Surgical robotics maker Shenzhen Edge Medical Co. Ltd. reported its initial public offering on the Hong Kong Stock Exchange to raise HKD$1.19 billion (US$154 million) to advance its pipeline of surgical robotic systems and expand its geographic footprint to markets outside China. http://www.bioworld.com/articles/727307 Wed, 31 Dec 2025 11:00:00 -0500 https://www.bioworld.com/articles/727307-surgical-robotic-maker-shenzhen-edge-announces-154m-hkex-ipo Shenzhen Edge Medical Co. Ltd.’s Multi-Port Endoscopic Surgical Robot Shenzhen Edge Medical Co. Ltd.’s Multi-Port Endoscopic Surgical Robot Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc. http://www.bioworld.com/articles/727660 Wed, 31 Dec 2025 09:00:00 -0500 https://www.bioworld.com/articles/727660-bayosthiti-ai-to-build-india-specific-rna-sequencing-ecosystem India map on technology concept background Livsmed Inc. closed the year’s biggest Kosdaq IPO with a ₩135.85 billion (US$94 million) haul Dec. 24. Livsmed specializes in the development of hand-held multi-joint laparoscopic surgical instruments for minimally invasive procedures. http://www.bioworld.com/articles/727284 Mon, 29 Dec 2025 11:00:00 -0500 https://www.bioworld.com/articles/727284-laparoscopic-instruments-maker-livsmed-tops-2025-kosdaq-ipos Livsmed Artisential Livsmed Artisential laparoscopic instrument. Credit: Livsmed Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc. http://www.bioworld.com/articles/727213 Tue, 23 Dec 2025 00:00:00 -0500 https://www.bioworld.com/articles/727213-bayosthiti-ai-to-build-india-specific-rna-sequencing-ecosystem India map on technology concept background Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its flagship product, the Sentire Endoscopic Surgical System. http://www.bioworld.com/articles/725991 Fri, 14 Nov 2025 11:00:00 -0500 https://www.bioworld.com/articles/725991-chinas-cornerstone-robotics-raises-200m-series-d-round Cornerstone Robotics Sentire Surgical System Cornerstone Robotics Sentire Surgical System. Credit: Cornerstone Robotics Ltd. Cyclana Bio Ltd. has closed a £5 million (US$6.7 million) pre-seed funding round. http://www.bioworld.com/articles/725282 Mon, 20 Oct 2025 09:00:00 -0400 https://www.bioworld.com/articles/725282-cyclana-bio-raises-funding-to-advance-approach-to-endometriosis Endometriosis In endometriosis, endometrial tissue, which typically only lines the uterus, migrates to other organs. Generating gametes from nonreproductive tissues could help overcome infertility. Previous studies have successfully transformed stem cells into viable oocytes through cellular reprogramming. Scientists at Oregon Health & Science University (OHSU) developed a method to derive them from skin cells via somatic cell nuclear transfer (SCNT), unlocking a mechanism that blends mitosis and meiosis. Now, the researchers have taken another step forward by generating fertilizable eggs from human skin cells. http://www.bioworld.com/articles/724671 Wed, 01 Oct 2025 09:00:00 -0400 https://www.bioworld.com/articles/724671-fertilizable-egg-like-cells-generated-with-dna-from-skin-cells Human SCNT oocyte with visible spindle before fertilization. Human SCNT oocyte with visible spindle (bright spot inside) before fertilization. Credit: Mitalipov laboratory, Oregon Health & Science University. Up to 71% of people carry at least one pathogenic variant that could contribute to development of a heritable disorder in offspring, but until now, prospective parents often had to undergo multiple tests to understand their risks. Pacific Biosciences of California Inc. (Pacbio)’s expanded Puretarget portfolio provides a quicker and more streamlined solution as it covers all challenging tier 3 genes identified in the American College of Medical Genetics technical standard. http://www.bioworld.com/articles/724458 Mon, 29 Sep 2025 12:00:00 -0400 https://www.bioworld.com/articles/724458-pacbios-puretarget-simplifies-carrier-screening Pacbio Revio sequencing plate Pacbio’s Revio system can process 100,000 samples per year to identify rare diseases. Credit: Pacific Biosciences of California Inc. Genescience Pharmaceuticals Co. Ltd. has synthesized sterols acting as estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) inhibitors reported to be useful for the treatment of endometriosis. http://www.bioworld.com/articles/724603 Mon, 29 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724603-genescience-pharmaceuticals-divulges-new-17-hsd1-inhibitors In what represents the first filing to have emerged in the name of Cellect Laboratories Inc., one of the start-up’s co-founders, Claire Theresa Murphy, describes their development of a non-invasive screening method that could one day replace the Pap test. http://www.bioworld.com/articles/724230 Wed, 24 Sep 2025 12:00:00 -0400 https://www.bioworld.com/articles/724230-cellect-develops-menstrual-products-for-cervical-cancer-screening Cellect cervical screening US20250288285-A1, “Functionalized nanomaterial for medical analyte collection”Assignee: Cellect Laboratories Inc.Inventors: Murphy, Claire Theresa; Klassen, Brandon William; Hung, Minren; Prophet, Lauren SarahIPC codes: A61B 5/15; A61B 5/00; A61F 13/20; A61B 10/02; A61F 13/47; A61F 13/472; A61F 13/512Publication date: Sep. 18, 2025Earliest priority details: US2024566776, March 18, 2024 Endocyclic Therapeutics (Endomet Biosciences Inc.) has been awarded a National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to accelerate the commercialization of ENDO-205, a nonhormonal, disease-modifying therapeutic designed to treat endometriosis. http://www.bioworld.com/articles/724279 Wed, 17 Sep 2025 09:00:00 -0400 https://www.bioworld.com/articles/724279-endocyclics-endo-205-awarded-nih-grant-for-endometriosis Illustration of ovaries and uterus with endometriosis Researchers from the University of California, Davis (UC-Davis) continue to assemble intellectual property in support of their development of methods and techniques which improve the accuracy of wearable sensor technologies. http://www.bioworld.com/articles/723457 Fri, 29 Aug 2025 12:00:00 -0400 https://www.bioworld.com/articles/723457-storx-sensors-monitor-fetal-health-during-labor-and-delivery Storx Sensors WO2025171056-A1, “Deep harmonic finesse: signal separation in wearable systems with limited data.”Assignee: The Regents of The University of California}Inventors: Ghiasi, Soheil; Saffarpour, MahyaIPC codes: G06F 18/2134; A61B 5/00; G06N 3/02Publication date: Aug. 14, 2025Earliest priority details: US2024550021, Feb. 24, 2024 Humanwell Healthcare (Group) Co. Ltd. has described fused ring compounds acting as angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of disorders of the ovary and female reproductive tract, metabolic diseases, cardiovascular, eye, gastrointestinal, neurological, renal and respiratory disorders. http://www.bioworld.com/articles/722630 Tue, 29 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/722630-humanwell-healthcare-identifies-new-angiotensin-at2-receptor-antagonists A healthy life for a healthy heart is a popular saying. However, even when following good habits, heart health can be already compromised from the very earliest stages of development. Maternal cells reach the embryo through the placenta contributing to its normal formation. So, just as the mother helps form a functional heart, she can also induce a condition that may not appear until adulthood. http://www.bioworld.com/articles/721717 Wed, 02 Jul 2025 09:00:00 -0400 https://www.bioworld.com/articles/721717-crvbc-cardiac-diseases-can-start-in-utero-after-immune-migration Illustration of anatomy of a human embryo at 7 weeks The U.K. government will offer women home-testing kits for cervical screening as part of an effort to tackle barriers and get more of them taking this potentially life-saving test. http://www.bioworld.com/articles/721217 Tue, 24 Jun 2025 12:00:00 -0400 https://www.bioworld.com/articles/721217-uk-women-to-be-offered-home-testing-kits-for-cervical-screening Cervical cancer cell Cervical cancer cell. Pregnant women with type 1 diabetes who used a hybrid closed loop automated insulin delivery system averaged more than three additional hours per day in their recommended glucose range than those who managed their diabetes with insulin injections or non-automated pump systems, a study presented at the 85th Scientific Sessions of the American Association in Chicago demonstrated. http://www.bioworld.com/articles/721215 Tue, 24 Jun 2025 12:00:00 -0400 https://www.bioworld.com/articles/721215-aid-system-improves-glycemic-control-in-pregnancy Pregnancy